Jacob Van Naarden

Jake Van Naarden serves as executive vice president and president of Lilly Oncology for Eli Lilly and Company. In this role, Jake oversees all aspects of oncology spanning discovery through commercial.

Jake joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. Following the acquisition, Jake played a key role in establishing the oncology research and development program.

In his earlier roles, Jake worked in various biotechnology investing, operational, and advisory capacities, including positions with HealthCor Management, Aisling Capital, and Goldman Sachs.

Jake received his A.B. degree in molecular biology from Princeton University.